Navigation Links
Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
Date:5/7/2009

WALTHAM, Mass., May 7 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that it will host a conference call and webcast on Thursday, May 14, 2009, at 4:30 p.m. EDT to review the Company's new business developments and first quarter financial results.

To access the live call, dial 877-397-0291 (domestic) or 719-325-4857 (international). The live webcast and replay access of the teleconference will be available on the Investors section of the Company's Website at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI), is a genetics-focused personalized health company that develops preventative consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventative and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1

Related medicine news :

1. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
2. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
3. T cell immunity enhanced by timing of interleukin-7 therapy
4. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
5. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
6. Interleukin-12 indicates survival prospects for melanoma patients
7. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
8. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
9. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
10. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
11. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4New Executive Leadership and CEO Announced for BiPar Sciences 2Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2 26quot 3BAprima Medical Software Inc 26quot 3B Unveiled by iMedica 3B Premier EHR PM Company Adopts New Name 51818 1 26quot 3BAprima Medical Software Inc 26quot 3B Unveiled by iMedica 3B Premier EHR PM Company Adopts New Name 51818 2 26quot 3BAprima Medical Software Inc 26quot 3B Unveiled by iMedica 3B Premier EHR PM Company Adopts New Name 51818 3Key Protein Might Shield Brain Cells 51813 1Hard To Treat Diseases 28HTDS PK 29 Tender Order To Indonesia 51808 1Hard To Treat Diseases 28HTDS PK 29 Tender Order To Indonesia 51808 2